Assessing treatment effectiveness of the 'Repurposing-Drugs-in-Oncology' (ReDO) protocol for cancer: The ReDO cancer treatment study

Not Applicable

• Conditions: Cancer; Cancer - Any cancer

• Registration Number: ACTRN12623001164684
• Lead Sponsor: Dr Taufiq Binjemain

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-11-09
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

diagnosed with cancer
suggested for the ReDO protocol by the investigating doctor

Exclusion Criteria

planning to start cancer treatments other than the ReDO protocol in the next 5 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Circulating Tumour Cell (CTC) count in CTC/ml[blood test using the validated Cytology-based Isolation-by-SizE-of-Tumour (ISET) - CTC system (Rarecells), which consists of two steps, a0 the isolation of cancer cells by filtration from 10ml of blood, and b) microscopy to count the number of CTC per ml of blood 3 months after implementation of the full ReDO protocol compared to baseline, that is 5 months after 0 months (baseline)];Circulating Tumour Cell (CTC) count in CTC/ml[blood test as above - Isolation of CTC from blood by filtration and analyses by microscopy 6 months after implementation of the full ReDO protocol compared to baseline, that is 8 months after 0 months (baseline)]